# Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults

> **NCT00314054** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 27 (estimated)

## Conditions studied

- Hepatitis C
- Hepatic Insufficiency

## Interventions

- **DRUG:** HCV-796

## Key facts

- **NCT ID:** NCT00314054
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2008-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00314054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00314054, "Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00314054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*